tert-butyl 4-[3-(trimethylsilyl)prop-2-yn-1-ylidene]piperidine-1-carboxylate | 1107620-20-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-[3-(trimethylsilyl)prop-2-yn-1-ylidene]piperidine-1-carboxylate
• 英文别名: tert-Butyl 4-(3-trimethylsilylprop-2-ynylidene)piperidin-1-carboxyate；tert-butyl 4-(3-trimethylsilylprop-2-ynylidene)piperidine-1-carboxylate
• CAS: 1107620-20-1
• 化学式: C₁₆H₂₇NO₂Si
• 分子量: 293.481
• InChiKey: NQYSPIBAFDDMLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.82
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-[3-(trimethylsilyl)prop-2-yn-1-ylidene]piperidine-1-carboxylate 在 copper(l) iodide 、 四(三苯基膦)钯 、 四丁基氟化铵 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 4.25h， 生成 2-methyl-6-[3-(piperidin-4-ylidene)prop-1-yn-1-yl]pyridine
  参考文献：
  名称：

  Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: Discovery and computational modeling of a new series of ligands with nanomolar affinity

  摘要：

  Metabotropic glutamate receptor 5 (mGlu(5)) is a biological target implicated in major neurological and psychiatric disorders. In the present study, we have investigated structural determinants of the interaction of negative allosteric modulators (NAMs) with the seven-transmembrane (7TM) domain of mGlu(5). A homology model of the 7TM receptor domain built on the crystal structure of the mGlu(1) template was obtained, and the binding modes of known NAMs, namely MPEP and fenobam, were investigated by docking and molecular dynamics simulations. The results were validated by comparison with mutagenesis data available in the literature for these two ligands, and subsequently corroborated by the recently described mGlu(5) crystal structure. Moreover, a new series of NAMs was synthesized and tested, providing compounds with nanomolar affinity. Several structural modifications were sequentially introduced with the aim of identifying structural features important for receptor binding. The synthesized NAMs were docked in the validated homology model and binding modes were used to interpret and discuss structure-activity relationships within this new series of compounds. Finally, the models of the interaction of NAMs with mGlu(5) were extended to include important non-aryl alkyne mGlu(5) NAMs taken from the literature. Overall, the results provide useful insights into the molecular interaction of negative allosteric modulators with mGlu(5) and may facilitate the design of new modulators for this class of receptors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.008
• 作为产物：
  描述：

  3-溴-1-三甲基硅基-1-丙炔 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 2.25h， 生成 tert-butyl 4-[3-(trimethylsilyl)prop-2-yn-1-ylidene]piperidine-1-carboxylate
  参考文献：
  名称：

  Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

  摘要：

  DOI：

  10.1016/j.bmc.2021.116239

文献信息

• [EN] HETEROCYCLIC MGLU5 ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DE MGLU5
  申请人：RECORDATI IRELAND LTD

  公开号：WO2011029633A1

  公开（公告）日：2011-03-17

  Compounds (I) (R1 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotri cyclic group containing from 1 to 5 heteroatoms selected from N, O and S; R2 is H, an optionally substituted monocyclic aromatic group, or a C1-C5 heteroaromatic group containing from 1 to 4 heteroatoms selected from N, O and S; R3 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotri cyclic group containing from 1 to 5 heteroatoms selected from N, O and S; an optionally substituted mono-, bi- or tricyclic C6-C14 aryl group, an optionally substituted C3-C6 cycloalkyl group, or an optionally substituted C3-C6 cycloalkenyl group; each R4, independently for each position capable of substitution, is H or C1-C6 alkyl; R5 is H, halogen or C1-C6 alkyl; m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and --- is an optional double bond) and their enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful for the treatment of neuromuscular dysfunction of the lower urinary tract and also for the treatment of gastrooesophageal reflux disease; anxiety disorder; abuse, substance dependence and substance withdrawal disorders; neuropathic pain disorder, migraine and fragile X syndrome disorders.

  化合物（I）（其中R1为任选取代的含1至5个选自N、O和S的杂原子的C1-C13杂单环、杂双环或杂三环基团；R2为H、任选取代的单环芳香基团或含1至4个选自N、O和S的杂原子的C1-C5杂芳香基团；R3为任选取代的含1至5个选自N、O和S的杂原子的C1-C13杂单环、杂双环或杂三环基团，任选取代的单环、双环或三环C6-C14芳基团，任选取代的C3-C6环烷基团，或任选取代的C3-C6环烯基团；每个R4独立地为每个可取代位置上的H或C1-C6烷基；R5为H、卤素或C1-C6烷基；m为0、1或2；n为0、1或2；p为0、1、2、3、4、5或6；---为任选的双键）及其对映体、非对映体、N-氧化物和药学上可接受的盐，以及含有它们的药物组合物，可用于治疗下尿路神经肌肉功能障碍以及胃食管反流病；焦虑障碍；滥用、物质依赖和物质戒断障碍；神经性疼痛障碍、偏头痛和脆性X综合征障碍。
• Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5
  作者：Davide Graziani、Silvia Caligari、Elisa Callegari、Carlo De Toma、Matteo Longhi、Fabio Frigerio、Roberto Dilernia、Sergio Menegon、Luca Pinzi、Lorenza Pirona、Valerio Tazzari、Anna Elisa Valsecchi、Giulio Vistoli、Giulio Rastelli、Carlo Riva

  DOI：10.1021/acs.jmedchem.8b01226

  日期：2019.2.14

  analyses were performed on the synthesized series of compounds to investigate structure-activity relationships. Compounds 12, 32, and 49 of the carbamate, urea, and amide classes, respectively, showed the most suitable cytochrome inhibition and metabolic stability profiles. Among them, compound 12 showed excellent selectivity, solubility, and stability profiles as well as suitable in vitro and in vivo pharmacokinetic

  代谢型谷氨酸受体5（mGlu5）的负变构调节剂（NAMs）对于治疗多种中枢神经系统疾病具有广阔的前景。最近，我们报道了丙-2-炔基亚环烷基胺衍生物是mGlu5受体的有效NAM和选择性NAM。在这项工作中，我们探索了丙-2-亚基亚环烷基胺化合物的酰胺，氨基甲酸酯，磺酰胺和脲衍生物，旨在提高溶解度和代谢稳定性。对合成的一系列化合物进行了计算机分析和实验分析，以研究结构-活性关系。氨基甲酸酯，尿素和酰胺类化合物的化合物12、32和49分别显示出最合适的细胞色素抑制和代谢稳定性特征。其中，化合物12表现出优异的选择性，溶解性，和稳定性概况以及合适的体外和体内药代动力学特性。它在大鼠和狗中被高度吸收，并在焦虑症，神经性疼痛和下尿路模型中活跃。
• NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS
  申请人：Leonardi Amedeo

  公开号：US20090042841A1

  公开（公告）日：2009-02-12

  This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

  本发明涉及新型杂环化合物，具有选择性亲和力，可与代谢型受体mGlu5亚型结合，以及这种化合物的药物组合物，并且在治疗下尿路障碍，如下尿路神经肌肉功能障碍，以及治疗偏头痛和胃食管反流病（GERD）方面使用这些化合物和组合物。
• Heterocyclic derivatives as M-GLU5 antagonists
  申请人：Leonardi Amedeo

  公开号：US08518916B2

  公开（公告）日：2013-08-27

  This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

  本发明涉及新型杂环化合物，具有对代谢型受体mGlu5亚型的选择性亲和力，其制药组合物以及在治疗下尿路障碍，如下尿路神经肌肉功能障碍，以及治疗偏头痛和胃食管反流病（GERD）中使用这些化合物和组合物的用途。